达格列净用于维持性透析患者的多中心随机临床试验(DARE-ESKD-2)
该多中心随机对照试验纳入80例维持性透析患者,随机接受达格列净10mg每日一次或标准治疗24周。主要终点NT-proBNP变化组间差异无统计学意义(P=0.065),KCCQ评分、6分钟步行距离及超声心动图指标均无显著差异,安全性终点亦无差异。结论认为达格列净在维持性透析患者中安全,但未显示可证实的心血管获益。
要点
- 达格列净10mg每日一次在维持性透析患者中安全性良好。
- 24周内NT-proBNP变化组间差异无统计学意义(P=0.065)。
- KCCQ评分、6分钟步行距离及超声心动图指标均无显著改善。
核心结论
- 达格列净在维持性透析患者中安全,但与标准治疗相比未影响心力衰竭替代标志物,24周内未显示可证实的心血管获益。
研究设计与样本
- 前瞻性、随机、开放标签、盲法终点试验,在3个透析中心进行,2023年1月至2024年9月纳入80例维持性透析成人患者,随机接受达格列净10mg每日一次或标准治疗24周。
主要发现
- NT-proBNP调整后变化中位数(95%CI)对照组为13(-64至281)pg/ml,达格列净组为-109(-356至55)pg/ml,组间差异中位数(95%CI)为-155(-327至-33)pg/ml,P=0.065。
- KCCQ临床总结评分最小均方差异(95%CI)为7分(P=0.073),总总结评分为7分(P=0.094),6分钟步行距离差异为-0.9米(P=0.956)。
- 6分钟步行距离改善比例达格列净组34.5% vs 对照组40.0%(OR 1.27,95%CI 0.44-3.74,P=0.657),KCCQ临床总结评分改善比例18.8% vs 22.9%(OR 1.63,95%CI 0.33-9.12,P=0.548)。
- 超声心动图测量指标及安全性终点组间均无差异。
临床怎么用
- 对于维持性透析患者,使用达格列净10mg每日一次短期(24周)安全性良好,但不应期望通过该治疗获得显著的心力衰竭替代标志物改善或心血管获益。
局限性
- 样本量较小(80例),研究周期较短(24周),为开放标签设计,主要终点为替代标志物而非临床硬终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Dapagliflozin reduces heart failure (HF) incidence and hospitalizations in chronic kidney disease (CKD), but its efficacy and safety in patients on maintenance dialysis remain uncertain. METHODS: In this prospective, randomized, open-label, blinded end point trial performed at 3 dialysis clinics between January 2023 and September 2024, adults on chronic dialysis were randomized to once daily dapagliflozin 10 mg or standard care for 24 weeks. The primary end point was change in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. Secondary end points included changes in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores and 6-minute walk test distance (6MWTD). Exploratory analysis examined intergroup differences in echocardiographic measurements and laboratory tests. Safety analysis comprised adverse event rates. RESULTS: Of 110 screened individuals, 80 were consecutively assigned (mean age: 56 years; 54% male). The median (95% confidence interval [CI]) adjusted change in NT-proBNP was 13 (-64 to 281) pg/ml in the control group and -109 (-356 to 55) pg/ml in the dapagliflozin group. The intergroup difference in NT-proBNP change was not statistically significant after adjustment by baseline values (median [95% CI] difference: -155 [-327 to -33] pg/ml; P = 0.065). No difference was found between study arms regarding the least mean (95% CI) square difference (LSD) in KCCQ clinical summary score (7 points; P = 0.073), total summary score (7 points; P = 0.094), or 6MWTD (-0.9 m; P = 0.956). Dapagliflozin did not increase the proportion of patients with improvement in 6MWTD (34.5% vs. 40.0%; odds ratio [OR]: 1.27 [95% CI: 0.44-3.74]; P = 0.657) or KCCQ clinical summary score (18.8% vs. 22.9%; OR: 1.63 [95% CI: 0.33-9.12]; P = 0.548). No difference was found between study arms regarding echocardiographic measurements or safety end points. CONCLUSION: Dapagliflozin was safe but did not affect surrogate markers of HF compared with standard care in patients receiving maintenance dialysis, suggesting no demonstrable cardiovascular benefit over 24 weeks in this population.
引用
- Barreto J, Martins MP, Aparecida Moreira Silva C, et al. A Multicenter Randomized Clinical Trial of Dapagliflozin in Patients Receiving Chronic Dialysis (The DARE-ESKD-2 Trial). Kidney Int Rep. 2026. PMID: 41970273. doi:10.1016/j.ekir.2026.106355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。